Sunovion drug cuts binge eating days at higher dose

In a mixed bag of results from the SEP360-321 pivotal study, Sunovion's dasotraline met its primary endpoint of statistically significant decrease in number of binge days per week compared with placebo at the higher dose of 6 mg but not the lower dose of 4 mg. The company hasn't provided any more details, other than stating that they will be analyzed and presented at a future scientific meeting.